** Taysha Gene Therapies' TSHA.O shares down 8.5% to $6.35 before the bell on Thurs after $200 mln overnight follow-on priced

** TSHA late Weds announced 32.5 mln shares and pre-funded warrants to purchase 833,333 shares at $6, a 13.5% discount to their last sale

** Co intends to use net offering proceeds to fund regulatory and manufacturing development and anticipated commercial launch, if approved, of TSHA-102 in Rett syndrome and development of other pipeline candidates, among other purposes, per the prospectus

** Jefferies, Goldman Sachs, Piper Sandler and Cantor Fitzgerald joint bookrunners

** Dallas, Texas-based TSHA has ~287.4 mln shares outstanding

** Early Mon, co said it completed dosing of 17 patients in early-stage trial evaluating TSHA-102 for treatment of Rett syndrome, a rare neurodevelopmental disorder

** TSHA shares had risen past five sessions. At Weds close, stock up about 52% over the past three months and up 26% YTD

** All 13 analysts are bullish on the stock and their median PT is $12, per LSEG data